Unknown

Dataset Information

0

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.


ABSTRACT: We aimed to evaluate the impact of alternating lenvatinib (LEN) and trans-arterial therapy (AT) in patients with intermediate-stage hepatocellular carcinoma (HCC) after propensity score matching (PSM). This retrospective study enrolled 113 patients with intermediate-stage HCC treated LEN. Patients were classified into the AT (n = 41) or non-AT group (n = 72) according to the post LEN treatment. Overall survival (OS) was calculated using the Kaplan-Meier method and analyzed using a log-rank test after PSM. Factors associated with AT were evaluated using a decision tree analysis. After PSM, there were no significant differences in age, sex, etiology, or albumin-bilirubin (ALBI) score/grade between groups. The survival rate of the AT group was significantly higher than that of the non-AT group (median survival time; not reached vs. 16.3 months, P = 0.01). Independent factors associated with OS were AT and ALBI grade 1 in the Cox regression analysis. In the decision tree analysis, age and ALBI were the first and second splitting variables for AT. In this study, we show that AT may improve prognosis in patients with intermediate-stage HCC. Moreover, alternating LEN and trans-arterial therapy may be recommended for patients below 70 years of age with ALBI grade 1.

SUBMITTER: Shimose S 

PROVIDER: S-EPMC7796435 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.

Shimose Shigeo S   Iwamoto Hideki H   Tanaka Masatoshi M   Niizeki Takashi T   Shirono Tomotake T   Noda Yu Y   Kamachi Naoki N   Okamura Shusuke S   Nakano Masahito M   Suga Hideya H   Yamaguchi Taizo T   Kawaguchi Takumi T   Kuromatsu Ryoko R   Noguchi Kazunori K   Koga Hironori H   Torimura Takuji T  

Cancers 20210105 1


We aimed to evaluate the impact of alternating lenvatinib (LEN) and trans-arterial therapy (AT) in patients with intermediate-stage hepatocellular carcinoma (HCC) after propensity score matching (PSM). This retrospective study enrolled 113 patients with intermediate-stage HCC treated LEN. Patients were classified into the AT (<i>n</i> = 41) or non-AT group (<i>n</i> = 72) according to the post LEN treatment. Overall survival (OS) was calculated using the Kaplan-Meier method and analyzed using a  ...[more]

Similar Datasets

| S-EPMC8573180 | biostudies-literature
| S-EPMC8120780 | biostudies-literature
| S-EPMC8464794 | biostudies-literature
| S-EPMC7437076 | biostudies-literature
| S-EPMC8951695 | biostudies-literature
| S-EPMC9684293 | biostudies-literature
| S-EPMC3407414 | biostudies-literature
| S-EPMC8010824 | biostudies-literature
2022-08-22 | GSE211658 | GEO
| S-EPMC10561391 | biostudies-literature